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Abstract 35 
Non-Alcoholic Fatty Liver Disease (NAFLD) is associated with multi-organ (hepatic, skeletal muscle, 36 
adipose tissue) insulin resistance (IR). Exercise is an effective treatment for lowering liver fat but its 37 
effect on insulin resistance in NAFLD is unknown. 38 
We aimed to determine whether supervised exercise in NAFLD would reduce liver fat and improve 39 
hepatic and peripheral (skeletal muscle and adipose tissue) insulin sensitivity. Sixty nine NAFLD 40 
patients were randomised to 16 weeks exercise supervision (n=38) or counselling (n=31) without 41 
dietary modification. All participants underwent magnetic resonance imaging/spectroscopy to assess 42 
changes in body fat, and in liver and skeletal muscle triglyceride, before and following 43 
exercise/counselling. To quantify changes in hepatic and peripheral insulin sensitivity, a pre-44 
determined subset (n=12 per group) underwent a two-stage hyperinsulinaemic euglycaemic clamp 45 
pre- and post-intervention. Results are shown as mean (95% CI). 46 
Fifty participants (30 exercise, 20 counselling), 51 y (40, 56), BMI 31 kg/m2 (29, 35) with baseline 47 
liver fat/water % of 18.8 % (10.7, 34.6) completed the study (12/12 exercise and 7/12 counselling 48 
completed the clamp studies). Supervised exercise mediated a greater reduction in liver fat/water % 49 
than counselling [Δ mean change 4.7% (0.01, 9.4); P<0.05], which correlated with the change in 50 
cardiorespiratory fitness (r = -0.34, P = 0.0173).  51 
With exercise, peripheral insulin sensitivity significant increased (following high-dose insulin) despite 52 
no significant change in hepatic glucose production (following low-dose insulin); no changes were 53 
observed in the control group.  54 
Although supervised exercise effectively reduced liver fat, improving peripheral IR in NAFLD, the 55 
reduction in liver fat was insufficient to improve hepatic IR.  56 
 57 
Keywords: NAFLD, insulin resistance, exercise, liver fat and magnetic resonance spectroscopy. 58 
 59 
Summary statement 60 
In NAFLD, 16 weeks of supervised exercise offers an effective treatment to reduce liver fat and 61 
improve peripheral insulin resistance and cardiorespiratory fitness. Greater reductions in liver fat are 62 
needed to improve hepatic insulin resistance. This could probably be achieved by increasing the 63 
period of exercise supervision. 64 
  65 
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Introduction 66 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of histopathological abnormalities which 67 
increase the risk of chronic liver disease, hepatocellular carcinoma and cardiovascular disease (1). 68 
NAFLD arises from accumulation of liver fat, frequently complicating obesity and other insulin-69 
resistant states, co-existing with the metabolic syndrome (2, 3). NAFLD is associated with multi-70 
organ (hepatic, skeletal muscle and adipose tissue) insulin resistance (IR) (4, 5).  71 
Although certain anti-diabetes agents reduce liver fat (6, 7), the cornerstone of therapy is lifestyle 72 
modification through dietary intervention and/or physical activity (8, 9). Weight loss through dietary 73 
intervention has been shown to normalise moderate hepatic steatosis (12-13%) and hepatic IR (10, 74 
11). Considering that NAFLD patients tend to engage in less habitual leisure-time physical activity 75 
and be more sedentary, physical activity is also recommended (12, 13). Various modalities of exercise 76 
have been shown to be beneficial in reducing liver fat in NAFLD including aerobic (5, 14, 15) and 77 
resistance exercise (13), even without weight loss. A recent study addressing the dose-response 78 
relationship between aerobic exercise and reduction in liver fat suggests that even low volume, low 79 
intensity aerobic exercise can reduce liver fat without clinically significant weight loss (16). It is 80 
unclear to what extent reduction in liver fat following exercise is associated with improvements in 81 
hepatic and peripheral IR. This is of particular importance considering the high rates of incident type 82 
2 diabetes mellitus (T2DM) in NAFLD patients.  83 
We set out to determine the efficacy of supervised exercise training in reducing liver fat, and the 84 
relationship between reduction in liver fat and improvements in hepatic and peripheral IR using the 85 
gold standard method for measuring insulin resistance, a 2-step euglycaemic hyperinsulinaemic 86 
clamp.  87 
Experimental materials and Methods  88 
Design  89 
A 16-week randomised controlled trial of NAFLD patients, randomised to supervised moderate-90 
intensity aerobic exercise or conventional counselling (control group) (Clinical Trials.gov 91 
NCT01834300).  92 
Participants 93 
Patients were recruited through hepatology clinics where they were undergoing routine clinical care 94 
from 4 teaching hospitals, and studied in 2 centres, in Guildford and Liverpool. NAFLD was 95 
diagnosed clinically by a hepatologist after exclusion of (steatogenic) drug causes, viral or auto-96 
immune hepatitis (negative hepatitis B and C serology and auto-antibody screen), primary biliary 97 
cirrhosis and metabolic disorders (α1-antitrypin deficiency, Wilson’s disease).  98 
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Inclusion criteria were a diagnosis of NAFLD, being sedentary (<2 h/week low-intensity physical 99 
activity, no moderate- or high-intensity activity), non-smokers, with alcohol consumption <14 100 
(females) and <21 (males) units/week. Exclusion criteria were T2DM, ischaemic heart disease or 101 
contraindications to exercise. Participants were excluded from follow-up assessment if they deviated 102 
from their habitual diet and lost excessive weight.  103 
The study conformed to the Declaration of Helsinki and was approved by the local research ethics 104 
committees. All participants provided fully informed written consent. 105 
Protocol 106 
69 patients were randomly assigned on a 1:1 basis using a computer-generated sequence to 16 weeks 107 
supervised exercise or conventional counselling (control group) using SAS v 9.1, PROC PLAN 108 
software (Statistical Analysis System Institute, NC, USA). Figure 1 shows the CONSORT diagram.  109 
Supervised Exercise. After a familiarisation session, participants attended the university gymnasium 110 
weekly, wearing a heart rate monitor (Polar Electro Oy, Finland) and supervised by a trained exercise 111 
physiologist. Training intensity was based on individual heart rate reserve (HRR) ([Maximal HR 112 
during cardiorespiratory fitness testing] – [Resting HR]). Participants performed 3/week 30 min 113 
moderate (30% HRR) aerobic exercise (treadmill, cross-trainer, bike ergometer, rower) progressing 114 
weekly based on HR responses (5/week 45 min at 60% HRR by week 12). Throughout, participants 115 
were monitored via the Wellness SystemTM (Technogym U.K. Ltd., Bracknell, UK), which tracks 116 
exercise activity within designated fitness facilities or by repeated telephone or e-mail contact.  117 
No dietary modifications were made, confirmed by standard 3-day food diaries collected immediately 118 
before and after the intervention and analysed for macronutrient intake.  119 
Control Group. Participants were provided with advice about the health benefits of exercise in 120 
NAFLD but had no further contact with the research team. To minimise disturbance to behaviour, diet 121 
and physical activity were not monitored. 122 
Measurements 123 
Measurements were performed before and immediately after the intervention period. After overnight 124 
fast, venous blood was taken for measurement of glucose, liver function, lipid profile, adiponectin and 125 
leptin. 126 
After full medical history and physical examination, a single person at each centre measured body 127 
weight, blood pressure, height, waist (umbilical) and hip (greater trochanter) circumference and 128 
performed bioimpedance analysis (Tanita BC-420MA, Tokyo, Japan).  129 
Magnetic resonance methods were as previously described (17). Volumetric analysis of abdominal 130 
subcutaneous adipose tissue (SAT) and abdominal visceral adipose tissue (VAT) used whole-body 131 
axial T1-weighted fast spin echo scans (10 mm slice, 10 mm gap), the abdominal region being defined 132 
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from the slices between the femoral heads, top of liver and lung bases. Proton magnetic resonance 133 
spectroscopy (1H MRS) quantified intrahepatocellular lipid (IHCL) and intramyocellular lipid (IMCL) 134 
(17). In liver 3 voxels of interest were identified at standardised sites avoiding ducts and vasculature. 135 
In skeletal muscle a single voxel was identified in each of the tibialis anterior and soleus muscles, 136 
avoiding bone, fascia and neurovascular bundle. Single voxel spectroscopy was conducted at each of 137 
these five sites: voxel size was 20×20×20 mm, TE (echo time) 135 msec, TR (repetition time) 1500 138 
msec, with 64 acquisitions. 1H-MR spectra were quantified using the AMARES algorithm in the 139 
software package jMRUI-3.0 (18). Data were processed blind. Liver fat is expressed as the percentage 140 
of CH2 lipid signal amplitude relative to water signal amplitude after correcting for T1 and T2 (19), 141 
and intramyocellular lipid (IMCL) is expressed as CH2 lipid amplitude relative to total creatine 142 
amplitude after correcting for T1 and T2 (20). NAFLD was defined as mean IHCL > 5·3%, which 143 
corresponds in the present units (CH2/H20) to the cut off of 5.5% by weight advocated on the basis of 144 
a large healthy-population 1H MRS study (21) which took account of tissue density, water content and 145 
the relative proton densities of triglyceride and water to express IHCL as % by weight in terms more 146 
directly comparable with biochemical measurements. This cutoff is also in accordance with traditional 147 
definitions of fatty liver based on biochemical analysis (21). (Any IHCL value expressed here as x% 148 
CH2/H2O can be converted to y% by weight (i.e. 10 × y mg/g) by using y% = 97.1/[1 + (89.1/x%)], 149 
based on assumptions and data detailed in (21, 22)) 150 
Clamp. Participants were instructed to avoid strenuous physical activity for 48 h. Upon arrival 151 
intravenous cannulae were inserted into both antecubital fossae for blood sampling and infusion of 152 
stable isotopes, insulin and glucose. After unenriched blood samples, a primed infusion of [6,6-2H2] 153 
glucose (170 mg; 1.7 mg.min-1) was started. 5 baseline samples were taken from 100-120 min, when a 154 
2-step hyperinsulinaemic–euglycaemic clamp commenced: insulin infusion at 0.3 mU.kg-1.min-1 (low-155 
dose) for 120 min to measure insulin sensitivity of hepatic glucose production (HGP), then at 1.5 156 
mU.kg-1.min-1
 
(high-dose) for 180 min to measure insulin sensitivity of peripheral glucose uptake. 157 
Euglycaemia was maintained by adjusting a 20% glucose infusion, spiked with [6,6-2H2] glucose (7 158 
mg.g-1 glucose for low-dose, 10 mg.g-1 high dose) according to 5 min plasma glucose measurements 159 
using a glucose oxidase method (Yellow Springs Analyser). Blood samples were taken every 30 min, 160 
except for every 5 min from 210-240 min (low-dose steady-state) and 390-420 min (high-dose steady-161 
state).  162 
Plasma glucose concentration and enrichment time-courses were smoothed using optimal segments 163 
analysis (23). HGP and glucose uptake (rate of disappearance, Rd) (µmol.kg-1.min-1) were calculated 164 
using non-steady-state equations (24), assuming a volume of distribution of 22% body weight. HGP 165 
was calculated at steady-state basally (90-120 min) and following low-dose insulin (210-240 min), 166 
corrected for fat-free mass and (since HGP is inversely related to [insulin]) multiplied by mean 167 
steady-state [insulin] (pmol.ml-1) at low-dose. Glucose Rd was calculated at steady-state following 168 
 6 
high-dose insulin (390-420 min) and metabolic clearance rate (MCR) (ml.kg-1.min-1) was calculated at 169 
basal and high-dose insulin steady-state (390-420 min) as (glucose Rd)/[glucose]. Glucose MCR and 170 
Rd were corrected for fat-free mass and (since they are directly related to [insulin]) divided by mean 171 
steady-state [insulin] (pmol.l-1) at basal and high-dose.  172 
Cardiorespiratory fitness assessment In Liverpool, cardiorespiratory fitness was assessed on a 173 
treadmill ergometer following the Bruce protocol (25). Following 2 min warm up at 2.2 km/h on the 174 
flat, initial workload was set at 2.7 km/h at 5° grade, then speed and grade increased step-wise every 175 
minute. Heart rate and rate of perceived exertion were monitored throughout. VO2peak
 
was calculated 176 
from expired gas fractions (Oxycon Pro, Jaegar, Hochberg, Germany) as the highest consecutive 15 s 177 
rate in the last minute before volitional exhaustion, or when heart rate and/or VO2 reached a plateau 178 
(21). In Guildford, VO2peak was performed on an electronically-braked bicycle ergometer (Lode; 179 
Excaliber Sport, Groningen, the Netherlands) with breath analyser (Medical Graphics, St Paul, MN, 180 
USA). Heart rate was measured throughout. After 2 min warm up at 50 W, resistance increased step-181 
wise at 20 W/min until volitional exhaustion (26). Cardiorespiratory fitness was defined as VO2peak 182 
identically at each facility (despite the different exercise modalities), expressed per kg body weight. 183 
Biochemistry. Baseline plasma samples were analysed using an Olympus AU2700 (Beckman Coulter, 184 
High Wycombe, UK) in Liverpool and an Advia 1800 Chemistry System (Siemens Healthcare 185 
Diagnostics, Frimley UK) in Guildford, with standard proprietary reagents and methods: glucose with 186 
hexokinase, total cholesterol and high-density lipoprotein (HDL) with cholesterol esterase/oxidase, 187 
triglyceride with glycerol kinase and liver enzymes including alanine aminotransferase (ALT), 188 
aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) with International 189 
Federation of Clinical Chemistry (IFCC) kinetic UV (without pyridoxal phosphate activation). Intra- 190 
and inter- assay coefficients of variation were ≤10%. Low-density lipoprotein (LDL) was calculated 191 
using the Friedwald formula. At a single centre, serum insulin, plasma adiponectin and leptin were 192 
measured by RIA using commercial kits (Millipore Corporation, Billerica, MA; intra-assay CV 6%, 193 
5%, 5% respectively), irisin by ELISA (Phoenix Pharmaceuticals, Inc. Burlingame, CA; intra-assay 194 
CV 4.1%), fetuin-A by ELISA (Epitope Diagnostics, Inc. San Diego; intra-assay CV 4.8%) and serum 195 
NEFA (Wako Chemicals, Neuss, Germany; inter- assay CV 3.0%). Glucose isotopic enrichment was 196 
measured by GC-MS on a HP 5971A MSD (Agilent Technologies, Wokingham, Berks, UK)(27). IR 197 
was quantified using HOMA2-IR (28). Indices of hepatic insulin resistance (Hepatic-IR) and adipose 198 
tissue insulin resistance (Adipose-IR) were calculated (29, 30). 199 
Diagnosis of metabolic syndrome was based on the National Cholesterol Education Program Adult 200 
Treatment Panel III criteria (31). Ten-year cardiovascular risk was calculated using the 10 year 201 
Framingham Risk Score (32). 202 
Statistical Analysis  203 
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Power calculation. The primary outcome variable was IHCL (% fat/water). Based on mean IHCL of 204 
20%, we considered 30% relative difference between groups to be clinically significant, implying 205 
mean IHCL of 20% and 14% in the control and exercise groups respectively. Based on a 2-sample t-206 
test, 5% 2-sided significance and standard deviation (SD) of 7.75% from previous studies, 56 patients 207 
(28 in each arm) were required to detect this 6% absolute IHCL difference with 80% power (27).  208 
Statistical methods. For the primary comparison of supervised exercise vs. control, delta (Δ) change 209 
from pre-intervention was calculated and analysed using linear regression (ANCOVA), with pre data 210 
as a covariate (33). Linear regression assumptions were assessed using Q-Q plots and scatter plots of 211 
studentised residuals versus fitted values. Where linear regression assumptions were not met these 212 
were resolved using the natural logarithm transformation. For exploratory and comparison purposes 213 
any continuous demographic variable within each group was also estimated using a paired t-test. 214 
Correlations were quantified using Spearman’s Rank correlation coefficient (rs). Data for continuous 215 
demographic variables are presented as median and inter-quartile range (IQR) and changes between 216 
supervised exercise compared to control are presented as mean (95% CI). Statistical analyses used 217 
Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). 218 
Unless otherwise stated, exact P-values are cited (values of “0.000” are reported as “<0.001”). Results 219 
are shown as mean (95% CI). 220 
Results  221 
Baseline characteristics Fifty patients completed the study [n=30 exercise (23 males, 7 female) and 222 
n=20 control (16 males, 4 female)] (Figure 1). The age of the participants was similar in the exercise 223 
[50y (46, 58), BMI 30.7 kg/m2 (29.2,32.9)] vs. control groups [52y (46, 59), BMI 29.7kg/m2 224 
(28.0,33.8)]. An equal number (n=15) completed the exercise in each centre (total exercise=30); 8 225 
controls completed in Liverpool and 12 controls completed in Guildford, Surrey (total controls n=20). 226 
Pre-intervention characteristics of the groups were similar with respect to age, VO2peak, biochemical 227 
and metabolic characteristics, and body composition (Tables 1 and 2).  228 
Changes in dietary intake In the exercise group after 16 weeks, total energy intake and macronutrient 229 
composition remained unchanged compared with baseline: energy [0.4 MJ (-0.4, 1.2), P=0.40)], 230 
protein [0.4 g (-11.6, 12.0), P=0.97], carbohydrate [6.4 g (-24.2, 37.0), P=0.34], sugars [-9.2 g (-27.2, 231 
30.0), P=0.41] and fat [9.8 g (8.5, 22.0), P=0.44]. 232 
Changes in body composition and biochemistry The primary outcome measure of IHCL in the 233 
exercise group was significantly reduced after 16 weeks: 19.4% (14.6, 36.1) vs. 10.1% (6.5, 27.1), but 234 
not in the control group: 16.0% (9.6, 32.5) % vs. 14.6 (8.8, 27.3). Supervised exercise mediated a 235 
greater IHCL reduction than in the controls [-4.7 % (-9.4, -0.01); P<0.05] (Table 2). Changes in ALT, 236 
AST and in GGT were not significant.  237 
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SAT reduction with exercise was significantly greater than with control [-1.8L (= -3.0, -0.7); 238 
P=0.003], but changes in VAT were not [-0.7L (-1.6, 0.2); P<0.109], and nor were changes in IMCL 239 
in soleus and tibialis anterior (Table 1). 240 
The changes in fasting plasma insulin and HOMA2-IR [-0.5 (-1.0, 0.02; P=0.06] with exercise were 241 
not significantly different compared with control, nor were those in adiponectin, leptin, irisin or fetuin 242 
(Table 2). 243 
Changes in cardiorespiratory fitness Cardiorespiratory fitness (expressed as ml/kg/min) significantly 244 
improved in the exercise group after 16 weeks: 23.7 ml/kg/min (21.7, 27.8) vs. 32.3 ml/kg/min (27.6, 245 
38.0); there was no significant increase in the control group: 23.2 ml/kg/min (20.9, 25.6) vs. 23.1 246 
ml/kg/min (20.9, 26.9). Exercise mediated a greater improvement compared to control [7.3 ml/kg/min 247 
(5.0, 9.7); P<0.001].  248 
Cardiorespiratory fitness (expressed as absolute values in l/min) significantly improved in the exercise 249 
group after 16 weeks: 2.45 l/min (2.22, 2.69) vs. 3.05 l/min (2.77, 3.34); there was no significant 250 
increase in the control group: 2.31 l/min (2.05, 2.63) vs. 2.30 l/min (2.04, 2.57). Exercise mediated a 251 
greater improvement compared to control [0.72 l/min (0.42, 1.02); P<0.001].  252 
The greater fitness improvement was accompanied by greater reductions in total body weight [-2.5 kg 253 
(-3.9, -1.1); P<0.001)], waist circumference [-3.0 cm (-5, -1); P<0.05] and percentage fat mass [-1.9% 254 
(-3.0, -0.7]; P<0.01) compared to control (Table 1). Changes in IHCL were significantly correlated 255 
with improvements in cardiorespiratory fitness (absolute and relative), total body weight and with 256 
reductions in visceral and subcutaneous fat (Figure 2).  257 
Changes in peripheral and hepatic insulin sensitivity In the subset of 24 patients that underwent the 2-258 
stage hyperinsulinaemic euglycaemic clamp, 12 patients in the exercise group and 7 patients in the 259 
controls completed the full clamp measurements. The changes in this exercise and control subset were 260 
similar to those seen in the whole group: [Liver fat, -9.3% (-18.1, 0.5) vs. 3.5% (-11.1, 3.9)] and 261 
VO2peak [7.7ml/kg/min (4.0, 11.1) vs. -1.4ml/kg/min (-4.4, 1.6)].  262 
Plasma glucose concentration at basal and during the clamp did not differ between interventions (data 263 
not shown). In the exercise group glucose infusion rate, corrected for [insulin], during the high-dose 264 
insulin infusion was higher post-exercise (P=0.009) (Figure 3a) but did not change in the control 265 
group. Following high-dose insulin infusion there was a significant increase in glucose Rd and MCR, 266 
corrected for [insulin] in the exercise group (P=0.02, P=0.004 respectively) with no significant 267 
change in the control group (Figure 3b and c). The change in glucose MCR was significantly different 268 
between groups (P=0.03).  269 
There was no significant difference with either intervention in HGP corrected for [insulin] at baseline 270 
or after low-dose insulin, (Figure 3d) or in the percentage decrease in HGP following low-dose insulin 271 
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in either the exercise group (pre-exercise 50.9±5.3 %; post-exercise 55.3±6.4 %) or the control group 272 
(pre 46.5±10.3 %; post 56.0±8.5 %). 273 
Changes in glucose MCR, corrected for insulin, under basal conditions were significantly correlated 274 
with changes in fitness (rs=0.48; P=0.04) but not in IHCL (rs=0.26; P=0.28). After high-dose insulin, 275 
the correlation with IHCL did not reach statistical significance (rs=0.43; P=0.18). 276 
Discussion 277 
We have demonstrated in a randomised controlled study that 16 weeks of supervised moderate-278 
intensity aerobic exercise in NAFLD reduces liver fat and that this was correlated with an 279 
improvement in cardiorespiratory fitness. Using a 2-step euglycaemic hyperinsulinaemic clamp in 280 
conjunction with quantification of liver fat, we showed, for the first time in patients with NAFLD, 281 
that the exercise-induced reduction in liver fat was accompanied by enhanced skeletal muscle and 282 
adipose tissue insulin sensitivity, with no improvement in hepatic glucose production.  283 
Various factors modulate liver fat, particularly regular physical activity (34, 35). Numerous studies 284 
have highlighted the therapeutic effects of endurance or resistance exercise in lowering liver fat in 285 
NAFLD, even without weight loss (15). However modest weight loss also has clinically significant 286 
effects on IHCL. In a study by Coker et al., measuring multi-organ insulin sensitivity in caloric 287 
restriction and exercise training (with and without weight loss), exercise with weight loss had the 288 
greatest effect both on visceral fat and hepatic glucose output suppression (36). However, liver fat 289 
was not measured, precluding direct comparison with the current study. 290 
In the current study, exercising participants lost ~3% of body weight and this will have contributed to 291 
the reduction in IHCL. In a 2-week dietary intervention in NAFLD, ~4% weight reduction was 292 
associated with 42% reduction in liver fat (37) while in the LOOK-AHEAD study, lifestyle 293 
intervention in T2DM resulting in 1-5% weight change produced 33% reduction in hepatic steatosis 294 
(14). While there are clearly weight-dependent effects, the correlation between a reduction in liver fat 295 
and improvement in cardiorespiratory fitness in the supervised exercise group suggests that the latter 296 
also is a major driver of IHCL levels. 297 
A significant improvement in peripheral (skeletal muscle and adipose) insulin sensitivity 298 
accompanied the reduction in liver fat following exercise. It is well documented that chronic exercise 299 
improves peripheral insulin sensitivity (38, 39). The improvement in peripheral insulin sensitivity 300 
following exercise training occurred without any change in intramyocellular lipid as has been shown 301 
in a previous study of overweight men (23). Petersen et al. (40), proposed that skeletal muscle IR 302 
promotes hepatic steatosis and metabolic syndrome, by altering post-prandial energy distribution, 303 
diverting glucose to the liver for de novo lipogenesis (DNL) and triglyceride synthesis. Furthermore, 304 
acute exercise through reversal of muscle IR, has been shown to reduce hepatic DNL by 30% and 305 
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hepatic triglyceride synthesis by 40% (41). In myostatin-null mice, increased muscle insulin 306 
sensitivity also protects against hepatic steatosis during high-fat feeding (42). Thus, skeletal muscle 307 
metabolism may influence hepatic triglyceride content and metabolism, with inter-organ ‘cross-talk’ 308 
between skeletal muscle, adipose tissue and liver (43). Although not measured here, myokines 309 
secreted by skeletal muscle after contraction appear to mediate this cross talk. Thus a plausible 310 
mechanism in our study for the reduction in liver fat is enhanced peripheral insulin sensitivity and 311 
increased skeletal muscle glucose uptake reducing the flux of plasma glucose to the liver for 312 
triglyceride synthesis. The critical role of adipose IR in the metabolic and histological changes in 313 
NAFLD, as well as its reversal using thiazolidinediones, has also been demonstrated (29, 44). In this 314 
study, we showed that adipose-IR could also be improved with exercise training.  315 
The lack of effect of the exercise programme on hepatic insulin resistance was surprising given the 316 
assumed links between liver fat accumulation and defective insulin suppression of glucose production 317 
(4, 45). Other studies have reported reduced hepatic steatosis and improved hepatic insulin resistance 318 
with weight loss following low calorie diets in NAFLD (10,11). However, in these studies liver fat 319 
was lower than in the current study and was reduced to normal by weight loss, from 12 to 2.5% (10) 320 
and from 12.8 to 2.9% (11). Although in our study there was a comparable loss of liver fat in the 321 
exercise group (9.3%) because the group had much higher liver fat levels at baseline (median 19.4%) 322 
many patients remained above the normal range after 16 weeks exercise. This suggests that greater 323 
reductions in liver fat are needed to improve hepatic insulin resistance, possibly to within the normal 324 
range. It is likely that this could be achieved by increasing the period of exercise supervision or the 325 
intensity of the exercise, or by caloric restriction (46). Sullivan et al. noted a similar dissociation 326 
between (reduced) liver fat and (unchanged) VLDL triglyceride synthesis rate, a metabolic pathway 327 
that also exhibits resistance to insulin, after exercise training in patients with NAFLD. Interestingly in 328 
the latter study, % liver fat was similar at baseline to the current study (5). Recent animal data may 329 
help provide a mechanistic explanation for the phenomenon of improved peripheral insulin 330 
sensitivity, reduced liver fat but impaired hepatic insulin sensitivity of glucose metabolism. This data 331 
suggests that within the liver glucose production and de novo lipogenesis have different insulin 332 
sensitivities: the gluconeogenic pathway is insulin-resistant (thus insulin cannot inhibit hepatic 333 
glucose production through gluconeogenesis) while the lipogenic pathway remains insulin-sensitive 334 
(thus insulin retains its ability to stimulate fatty acid synthesis) (47). This selective insulin resistance 335 
is explained by a bifurcation of the hepatic insulin signalling pathway: control of the repression of 336 
gluconeogenesis occurs through FoxO1, while a separate pathway controlling lipogenesis involves 337 
SREBP-1c(48). Although this cannot be tested in the current study, this mechanism would provide a 338 
plausible explanation for the dissociation of the effects of exercise on hepatic liver fat and hepatic 339 
glucose production.  340 
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We acknowledge limitations to the study. We used a per protocol analysis. The drop-out rate (19/69, 341 
28%) was higher than the anticipated 15-20%, 15 controls and 4 in the exercise group, apparently 342 
mainly for practical reasons (e.g. time constraints, excessive research burden) but we believe the 343 
disproportionately higher dropout rate in the control group reflects many participants’ underlying 344 
desire to be randomised to the exercise program. The higher dropout rate in the control group is, we 345 
cautiously argue, unlikely to bias our conclusion, and will of course not affect assessment of the effect 346 
of the exercise intervention per se. A further imitation is that cardiorespiratory fitness was assessed at 347 
study sites using two different modalities, treadmill vs. cycle ergometer. Whilst cardiorespiratory 348 
fitness may be lower using cycle ergometry, the primary comparison was the change in fitness with 349 
intervention, thus this is unlikely to bias our findings. This is likely due to the greater spread of 350 
VO2peak results given the improvements post exercise training. While we believe our cohort is 351 
representative of the general NAFLD population, there may be a selection bias with only the most 352 
motivated patients consenting to participate in an exercise intervention study: this may underlie the 353 
high dropout rate of controls. Accepting these limitations, the noteworthy strengths are the application 354 
of whole body MRI and 1H-MRS, the most sensitive, non-invasive method to quantitate liver fat, and 355 
measurement of corresponding changes in organ-specific insulin sensitivity. Using these gold 356 
standard techniques we provide important insight into the mechanism by which exercise mediates 357 
reduction in liver fat by enhanced peripheral (skeletal muscle) insulin sensitivity, without this 358 
reduction in liver fat being paralleled by improved hepatic insulin sensitivity.  359 
 360 
In summary, in patients with NAFLD exercise-induced reduction in liver fat is related to the 361 
improvement in cardiorespiratory fitness and accompanied by an improvement of peripheral (muscle 362 
and adipose) but not hepatic IR. The greatest benefit in normalising liver fat, improving both 363 
peripheral and hepatic IR and potentially providing the greatest protection against incident T2DM, 364 
may require increasing the duration and/or intensity of the exercise supervision, in conjunction with 365 
caloric restriction.  366 
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 385 
Clinical Perspectives 386 
 NAFLD represents a common obesity-related complication, increasing the risk of type 2 diabetes 387 
mellitus, cardiovascular disease and chronic liver disease. Exercise interventions are effective in 388 
reducing liver fat, even without significant weight loss.  389 
 We demonstrate exercise supervision is effective at reducing liver fat and this was related to an 390 
improvement in cardiorespiratory fitness. As expected exercise was associated with significant 391 
improvements in peripheral (skeletal muscle and adipose tissue) insulin resistance. 392 
 Surprisingly, despite significant reductions in liver fat with exercise, we did not observe an 393 
improvement in hepatic insulin resistance. We speculate that persisting elevated liver fat even after 394 
exercise training, means undiminished hepatic insulin resistance. Exercise training needs to be 395 
more prolonged or more intense to achieve a greater reduction in liver fat. These results have 396 
potential public health implications considering the associated long-term metabolic, hepatic and 397 
cardiovascular complications.  398 
 399 
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Figure legends 551 
 552 
Figure 1. CONSORT diagram showing flow of participants through the study. 553 
Figure 2. Black circles indicate individuals in the exercise group; open circles indicate individuals in 554 
the control group. 555 
A) Relationship between reduction in liver fat (IHCL) and improvement in cardiorespiratory 556 
fitness (VO2peak ml.kg-1.min-1) (r= -0.34; P=0.02) 557 
B) Relationship between reduction in IHCL and reduction in body weight (r=0.48; P<0.001) 558 
C) Relationship between reduction in IHCL and reduction in visceral adipose tissue volume 559 
(VAT) (r=0.37; P=0.008). 560 
D) Relationship between reduction in IHCL and reduction in subcutaneous adipose tissue 561 
volume (SAT) (r=0.61; P<0.001). 562 
Figure 3. Rates of a) glucose infusion (GINF) during high dose insulin, b) glucose uptake (Rd) during 563 
high dose insulin, c) glucose metabolic clearance (MCR) during high dose insulin and d) hepatic 564 
glucose production (HGP) during low dose insulin expressed relative to insulin, before (grey bars) 565 
and after (black bars) exercise or controls. 566 
 567 
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Table 1. Clinical, biochemical and MRI-measured body composition in 50 patients before and after supervised exercise intervention (Ex; n=30) and control 
(Con; n=20) (reported as median and interquartile range as within group comparison). Mean delta changes with 95% confidence intervals (with significance 
values) are shown for each intervention and the delta changes are compared (between group comparison). *P<0.05; **P<0.001 
 
 Within-group comparison Between-group comparison 
 Pre Ex 
Median (IQR) 
Post Ex 
Median (IQR) 
Pre Con 
Median (IQR) 
Post Con 
Median (IQR) 
Ex Δ Change  
Mean (95 % CI) 
Con Δ Change 
 Mean (95% CI) 
Δ Mean (95% CI) 
 
P 
Weight (kg) 95.6 (83.8-104) 90.7 (80.1-101.5)  90.4 (86.5-107.5) 90.7 (86.4-108.5) -2.5 (-3.5, -1.4)** 0.2 (-0.8, 1.1) -2.5 (-3.9, -1.1) 0.001 
BMI (kg/m2) 30.6 (29.0-32.9) 30.0 (27.9-32.0) 29.7 (28.0-33.8) 29.9 (28.0-33.0) -0.9 (-1.4, -0.5)** 0.02 (-0.5, 0.6) -1 (-1.3, -0.3) 0.007 
Waist (cm) 106 (101-112) 103 (95-109) 102 (99-114) 101 (98-114) -4.1 (-5.8, -2.4)** -1.01 (-2.45, 0.34) -3 (-5, -1) 0.013 
% fat mass 30.4 (25.9-32.1) 28.0 (24.3-29.8) 31.0 (26.5-37.7) 30.7 (25.8-37.0) -1.6 (-2.4, -0.7)** 0.2 (-0.6, 1.1) -1.9 (-3.0, -0.7) 0.002 
Systolic BP (mmHg) 135 (125-142) 129 (121-137) 125 (118-142) 132 (123-143) -5 (-9, -1)* 1 (-5, 7) -4. (-10, 1.0) 0.111 
Diastolic BP  83 (75-87) 78 (74-82) 82 (72-92) 83 (72-90) -4 (-7, -0.3)* -3 (-9, 3) -2 (-5, 3) 0.456 
VO2peak(ml/kg/min)^ 23.7 (21.7-27.8) 32.3 (27.6-38.0) 23.2 (20.9-25.6) 23.1 (20.9-26.9) 7.2 (5.3, 9.1)** -0.2 (-1.7, 1.3) 7.3 (5.0,9.7) <0.001 
ALT^ (U/l) 45 (36-66) 32 (25-44) 47 (29-63) 34 (24-51) -14 (-23, 5)** -12(-19, -4)** 0.99 (0.78, 1.20) 0.760 
AST^ (U/l) 33 (25-47) 29 (22-35) 31 (23-41) 27 (23-36) -8 (-12, -3)** -4 (-8,1) 0.92 (0.79, 1.07) 0.268 
GGT^ (U/l) 47 (35-62) 34 (22-48) 42 (28-66) 41 (26-68) -18 (-29, -7)** -8(-18, 2) 0.87 (0.74, 1.02) 0.089 
Cholesterol (mmol/l)  5.1 (4.7-5.7) 4.8 (4.4-5.3) 5.2 (4.60-5.49) 5.1 (4.53) -0.19 (-0.38, 0.01) 0.02 (-0.18, 0.22) -0.20 (-0.49, 0.09) 0.169 
Triglycerides 
(mmol/l) 
1.9 (1.4-2.63) 1.7 (1.3-2.2) 1.5 (1.2-2.7) 1.6 (1.4-2.7) -0.16 (-0.37, 0.04) 0.05 (-0.40, 0.50) -0.24 (-0.54, 0.07) 0.123 
HDL (mmol/l) 1.2 (0.9-1.4) 1.2 (0.9-1.4) 1.2 (0.9-1.3) 1.1 (0.9-1.3) 0.02 (-0.02, 0.06) 0.00 (-0.06, 0.06) 0.03 (-0.04, 0.09) 0.443 
LDL (mmol/l) 3.5 (3.0-3.9) 3.2 (2.8-3.5) 3.4 (2.6-3.7) 3.1 (2.5-3.5) -0.29 (-0.5, -0.1)* -0.26 (-0.56, 0.03) 0.06 (-0.29, 0.40) 0.745 
Chol:HDL ratio 4.6 (4.0-5.1) 4.0 (3.3-5.0) 4.7 (4.0-5.6) 4.6 (4.0-5.2) 0.3 (-0.0-0.5)* -0.09 (-0.44, 0.27) -0.21 (-0.61, 0.18) 0.279 
Liver fat (% 
CH2/water) 
19.4 (14.6-36.1) 10.1 (6.5-27.1) 16.0 (9.6-32.5) 14.6 (8.8-27.3) -9.3 (-13.1, -5.3)* -2.5 (-6.2, 1.2) -4.7 (-9.4, 0.01) 0.05 
VAT (l) 9.8 (8.0-11.7) 8.6 (7.8-9.6) 7.8 (6.9-9.2) 8.0 (6.9-9.1) -1.0 (-1.6, -0.4)* -0.2 (-0.8, 0.5) -0.7 (-1.6, 0.2) 0.109 
SAT (l) 23.1 (19.4-32.0) 20.7 (17.5-28.3) 21.7 (19.6-29.1) 23.1 (19.1-29.3) -1.4 (-2.6, -1.0)* 0.01 (-0.8, 0.9) -1.8 (-3.0, -0.7) 0.003 
Abdominal fat (l)  33.2 (29.1-41.0) 29.9 (26.7-37.2) 30.0 (27.5-38.2) 31.9 (27.1-37.5) -2.8 (-4.0, -1.6)* -0.15 (-1.6, 1.3) -2.7 (-4.6, -0.8) 0.006 
VAT:SAT ratio  0.4 (0.3-0.6) 0.4 (0.3-0.5) 0.4 (0.3-0.4) 0.3 (0.3-0.4) -0.01 (-0.03, 0.00) -0.01 (-0.02, 0.01) 0.00 (-0.03, 0.02) 0.853 
IMCL Soleus  
(CH2/creatine) 
12.3 (9.0-16.8) 12.8 (9.2-15.6) 15.5 (11.7-21.8) 15.0 (12.9-21.4) -0.8 (-2.7, 1.2) -1.1 (-1.8, 4.1) -1.9 (-5.0, 1.3) 0.237 
IMCL Tibialis Ant.  9.0 (5.6-11.2) 8.6 (6.8-11.6) 7.3 (5.3-9.5) 8.7 (7.1-11.7) 0.2 (-2.3, 2.8) -0.9 (-9.3, 7.6) 1.0 (0.7, 1.3) 0.848 
Within-group comparisons use paired t-tests, p < 0.05 being taken as evidence of a significant change pre- to post-intervention: a negative change indicates reduction pre- to 
post. Between-group comparisons (final two columns) use linear regression (ANCOVA) comparing post-scores between groups correcting for pre-scores, Δ therefore indicates 
 22 
the difference between post-intervention means after correcting for pre-intervention scores: a negative difference indicates a lower mean for the exercise group compared with 
control. ^ indicates that a log transformation was necessary to meet the assumptions of linear regression; here, Δ is the ratio of geometric means post-intervention after 
correcting for pre-intervention scores, a ratio <1 indicating a lower mean in exercise group relative to control.
 23 
Table 2. Metabolic measurements in 50 patients before and after supervised exercise intervention (Ex; n=30) and control (Con; n=20) (reported as median 
and interquartile range as within group comparison). Mean delta changes with 95% confidence intervals (with significance values) are shown for each 
intervention and the delta changes are compared (between group comparison). *P<0.05. 
 
 Within-group comparison Between-group comparison 
 Pre Ex 
Median (IQR) 
Post Ex 
Median (IQR) 
Pre Con 
Median (IQR) 
Post Con 
Median (IQR) 
Ex Δ Change  
Mean (95 % CI) 
Con Δ Change 
Mean (95% CI) 
Δ Mean 
(95% CI) 
Fasting glucose (mmol/l) 5.4 (4.8-6.1) 5.3 (4.9-5.7)* 5.6 (4.8-6.1) 5.5 (5.0-5.8)* -0.15 (-0.30, 0.00) -0.2 (-0.3, 0.0) 0.0 (-0.2, 0.2) 
Fasting insulin (pmol/l) 131 (96-162) 115 (72-158)* 119(96-193) 130 (95-195) -22 (-43, -1) 2 (-19, 23) -26 (-55, 2) 
HOMA2-IR 2.5 (1.8-3.0) 2.1 (1.3-2.9)* 2.2 (1.8-3.6) 2.5 (1.8-3.7) -0.43 (-0.81, -0.05) 0.03 (-0.3, 0.4) -0.5 (-0.1.0, 0.02) 
Fasting FFA (mmol/l)  0.52 (0.45-0.60) 0.42 (0.35-0.59) 0.56 (0.39-0.71) 0.54 (0.42-0.65) -0.04 (-0.11, 0.03) -0.03 (-0.08, 0.03) -0.03 (-0.1, 0.1) 
Adipose–IR (mmol/l.pmol/l) 61 (48-88) 50 (30-86)* 55. (47-87) 60 (44-84) -15 (-27, -2) -0.5 (-17, 16) -18 (-36, 0.5)* 
Adiponectin (ng/ml) 5950 (3700-8100) 5450 (3550-7650) 6300 (5200-7950) 6650 (4950-9750) -260 (-790, 269) 259(-543, 1060) -630(-1497, 238) 
Leptin (ng/ml) 9.2 (6.5-12.6) 7.1 (4.3-11.9)* 11.8 (7.0-18.5) 11.8 (6.9-19.0) -1.7 (-3.0, -0.4)* -0.3 (-1.5, 1.0) -1.7 (-3.5, 0.1) 
Irisin (ng/ml) 140 (128-171) 129 (121-173)* 140 (128-179) 145 (123-156) -10.5 (-18.9, -2.1) -5.4 (-16, 5.1) -4.7 (-17, 8) 
Fetuin-A *(µg/ml) 483 (412-518) 470(397-506) 424 (393.8 -
4780.0) 
428 (394-477) -1.9 (-15.5, 11.6) -4.0 (27, 19) -2. (-28, 24) 
 
Within-group comparisons use paired t-tests, P<0.05 being taken as evidence of a change pre- to post-intervention: a negative change indicates reduction pre- to post. 
Between-group comparisons use linear regression (ANCOVA) comparing post scores between groups whilst correcting for pre-scores, therefore indicates the difference 
between post intervention means after correcting for pre-intervention scores: a negative difference indicates a lower mean for the exercise group compared with control 
group. 
 
 
